DEVELOPMENT OF BORON CHELATES APPLIED IN NEUTRON CAPTURE THERAPY
Cancer, BNCT, B-10, acute toxicity.
In this work, the compound levan-boron was synthesized as a new candidate for boron neutron capture therapy. The compound was characterized by spectroscopy in the infrared region showing bands in the regions of 1349 cm-1 (vB-O-C) and 1128 cm-1 (vBO4), electronic absorption spectroscopy, and nuclear magnetic resonance of 1H, 13C and 11B. After confirmation of its chemical structure, levan-boron solutions were irradiated with a thermal neutron beam in a reactor containing sources of americium-beryllium (AmBe) for periods of 19, 27 and 30 days, then, emission spectrometry analyzes were carried out (ICP-OES) to determine boron concentrations after 10B(n,α) 7Li nuclear reaction and observe 10B→7Li conversion rates. Cytotoxicity tests were carried out against Vero and MCF-7 cell lines and acute toxicity (OECD 423 Protocol). The results of these tests showed a percentage of cell viability between 70- 88% and 72-83%, respectively. The boron compound presented toxicological classification in category 5 in acute toxicity, which is very promising since it can proceed to irradiation tests in tumor cells and in vivo using animal experimentation.